Long-term Safety and Efficacy of Indacaterol, a Long-Acting β2-Agonist, in Subjects With COPD.

The article focuses on a study on the long-term safety and efficacy of indacaterol in managing patients with chronic obstructive pulmonary disease (COPD). The study determines whether the long-acting β2-agonist (LABA) can still be effective beyond 12 weeks of treatment. It discusses results related to adverse events such as nasopharyngitis and cough. It concludes that indacaterol, taken once daily for a year, offers effective and sustained bronchodilation to COPD patients.